Condition: Muscular Diseases · Neuromuscular Manifestations · Autoimmune · Sponsor: Arcellx, Inc.
A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.
This description comes directly from the study's public registry record.
Clinical Information · 240-327-0379 · clinical@arcellx.com
Always discuss trial participation with your own doctor first.
| UCLA Medical Center | Los Angeles, California, United States | Recruiting |
| University of California, Irvine | Orange, California, United States | Recruiting |
| Stanford Hospital | Palo Alto, California, United States | Recruiting |
| University of South Florida - Carol and Frank Morsani Center of Advanced Healthcare | Tampa, Florida, United States | Recruiting |
| Karmanos Cancer Institute | Detroit, Michigan, United States | Recruiting |
| University of Minnesota Delaware Clinical Research Unit | Minneapolis, Minnesota, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
| Columbia University Irving Medical Center | New York, New York, United States | Recruiting |
| Ohio State University | Columbus, Ohio, United States | Recruiting |
| Oregon Health & Science University (OHSU) | Portland, Oregon, United States | Recruiting |
| Temple University Hospital | Philadelphia, Pennsylvania, United States | Recruiting |
| UT Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
+ 1 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06626919